Abstract Library

#831 Overall Survival (OS) as a Function of the Number of Therapeutic Lines in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDpNET)

Introduction: At least 9 therapeutic options are now available for unresectable WDpNET patients. Whether all lines can be administrated before tumor or toxic-related deaths is currently unknown.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Berdelou A, Malka D, Leboulleux S, Boige V, Chougnet C,

Keywords: pNets,

#507 Are all Metastatic Grade 3 WHO 2010 Neuroendocrine Carcinoma Poorly Differentiated?

Introduction: The WHO classification 2010 for neuroendocrine tumors (NET) defines poorly differentiated neuroendocrine carcinomas (NEC) as grade 3 (G3) according to mitoses> 20/10 HPF and/or Ki-67>20%.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Vélayoudom-Céphise F, Duvillard P, Malka D, Leboulleux S, Guigay J,

Keywords: proliferation index, neuroendocrine tumors,

#320 Predictors of Clinical Response to Everolimus in Patients with Well-differentiated Metastatic Pancreatic NETs

Introduction: Everolimus (E) is an mTOR inhibitor with promising antitumor activity in patients with NETs. Predictor factors of response could improve the clinical use of this compound.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: De Martino M, Ducreux M, Dromain C, Duvillard P, Guigay J, Leboulleux S,

Keywords: everolimus, mTOR, RECIST, pancreas, neuroendocrine, tumor, proliferative index, predictor,

#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors

Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Fekih M, Baudin E, Ducreux M, Chougnet C, Leboulleux S,

Keywords: carcinoid tumor, neuroendocrine tumors, therapeutics, Somatostatin analogues, lung,

#282 Characteristics of Patients with Well-differentiated Metastatic Lung Neuroendocrine Tumors

Introduction: Characteristics of well-differentiated lung neuroendocrine tumors (WDLNET) are poorly characterized at the metastatic stage.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Chougnet C, Guigay J, Borget I, Leboulleux S, Duvillard P,

Keywords: lung NET, metastases, somatostatin analog, somatostatin recpetor scintigraphy ,